Biote Corp

biote Corp. is a woman-led company, which engages in providing bio identical hormone pellet therapy. It delivers a comprehensive, end-to-end platform that provides practitioners with medical education, training and certification, practice management software, and digital and point-of-care marketing support. The company is headquartered in Irving, TX.

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Biote Corp reports robust Q2 earnings, eyes men's health market

Biote Corp's Q2 2023 earnings call highlighted strong financial and strategic progress, marked by revenue growth, improved operating income, and a focus on expanding into new markets. While facing realignment challenges, the company remains confident in its outlook for continued growth and is dedicated to offering innovative wellness solutions.

Biote Corp reports revenue growth and plans nationwide wellness launch

Biote Corp (BTMD) demonstrated positive financial performance in Q3 2023 with revenue growth and improved EBITDA margin, driven by dietary supplements and procedures.
The company's strategic focus on expanding product offerings, engaging with key opinion leaders, and realigning sales territories positions them for future growth.
While facing challenges in procedure revenue growth and market dynamics, Biote Corp's initiatives to launch new offerings and target men's health present opportunities for expansion.

Biote Corp reports robust 2023 growth and targets strategic expansion

Biote Corp (BTMD) delivered strong financial performance in 2023 and sets ambitious targets for 2024, focusing on growth and efficiency.
The company's strategic initiatives, including new offerings and acquisitions, position it well for expansion and market leadership.
Challenges lie in optimizing operations and integration efforts, but Biote's commitment to innovation and growth bodes well for the future.

Biote Corp reports revenue growth and strategic acquisitions in Q1

Biote Corp (BTMD) delivered a solid performance in Q1 2024, marked by revenue growth, improved EBITDA, and strategic acquisitions.
While challenges like declining dietary supplement revenue and analyst inquiries exist, the company's strengths in product innovation and financial outlook bode well for future growth.
By capitalizing on opportunities in product development, geographic expansion, and market demand for wellness solutions, Biote Corp can further solidify its position in the industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

biote Corp. is a woman-led company, which engages in providing bio identical hormone pellet therapy. It delivers a comprehensive, end-to-end platform that provides practitioners with medical education, training and certification, practice management software, and digital and point-of-care marketing support. The company was founded in 2012 and is headquartered in Irving, TX.

The consensus price target hints at an 88% upside potential for biote Corp. (BTMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts See an 88.04% Upside in biote Corp. (BTMD): Can the Stock Really Move This High?

IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide third quarter financial results on Tuesday, November 12, 2024, after the close of the market. A conference call to discuss the firm's results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conference call ma.

Biote Schedules Third Quarter 2024 Financial Results Release and Conference Call

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is biote Corp. (BTMD) a Great Value Stock Right Now?

biote Corp. (NASDAQ:BTMD ) Q2 2024 Earnings Conference Call August 8, 2024 5:00 PM ET Company Participants Szymon Serowiecki – Investor Relations Terry Weber – Chief Executive Officer Bob Peterson – Chief Financial Officer Conference Call Participants Les Sulewski – Truist Securities Jonna Kim – TD Cowen Richard Magnusen – B. Riley Securities George Kelly – ROTH Capital Kaumil Gajrawala – Jefferies Operator Good day, and welcome to the Biote Second Quarter 2024 Earnings Conference Call.

biote Corp. (BTMD) Q2 2024 Earnings Call Transcript

IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Financial Highlights (All financial result comparisons made are against the prior-year period) Revenue of $49.2 million Procedure revenue of $38.4 million Gross profit margin of 68.9%, including a $1.2 millio.

Biote Reports Second Quarter 2024 Financial Results

Acme United

Carriage Services

Steelcase

Cash indicates a company's true financial health. It is the key to its existence, development and success.

Buy These 4 Stocks With Rising Cash Flows for Big Gains

IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide second quarter financial results on Thursday, August 8, 2024, after the close of the market. A conference call to discuss the firm's results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conference call may.

Biote Schedules Second Quarter 2024 Financial Results Release and Conference Call

biote Corp. (BTMD) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

biote Corp. (BTMD) is on the Move, Here's Why the Trend Could be Sustainable

Ardmore Shipping

GeoPark

TXO Energy Partners LP

Achieving profit is, no doubt, a company's goal, but having a healthy cash flow is imperative to its existence, development and success. So, ASC, TXO, GPRK and BTMD are worth buying.

Buy 4 Stocks With Rising Cash Flows to Enrich Your Portfolio

The average of price targets set by Wall Street analysts indicates a potential upside of 25.4% in biote Corp. (BTMD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Think biote Corp. (BTMD) Could Surge 25.44%: Read This Before Placing a Bet

biote Corp. (BTMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

biote Corp. (BTMD) Surges 10.4%: Is This an Indication of Further Gains?

IRVING, Texas--(BUSINESS WIRE)--biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced it has signed a binding term sheet with Marci M. Donovitz, stockholder of Biote, to resolve litigation (“Donovitz Litigation”). For $60 million in the aggregate, Biote will repurchase all of the approximately 8.3 million of the Paired Interests and/or Class.

Biote Announces $60 Million Agreement to Repurchase 8.3 Million Shares and Cancel Approximately 4.0 Million Earnout Shares

biote Corp. (NASDAQ:BTMD ) Q1 2024 Earnings Conference Call May 7, 2024 5:00 PM ET Company Participants Simon Serowiecki - Investor Relations Terry Weber - Chief Executive Officer Bob Peterson - Chief Financial Officer Marc Beer - Executive Chairman Ross McQuivey - Chief Medical Officer Conference Call Participants Les Sulewski - Truist Securities Jonna Kim - TD Cowen Kaumil Gajrawala - Jefferies George Kelly - ROTH MKM Operator Good day, and welcome to the Biote First Quarter 2024 Earnings Conference Call. [Operator Instructions] Please note, this event is being recorded.

biote Corp. (BTMD) Q1 2024 Earnings Call Transcript

Biote Corp. (BTMD) came out with quarterly earnings of $0.23 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to earnings of $0.94 per share a year ago.

Biote Corp. (BTMD) Q1 Earnings Beat Estimates

IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financial results for the first quarter ended March 31, 2024. First Quarter 2024 Financial Highlights (All financial result comparisons made are against the prior-year period) Revenue of $46.8 million, up 4.4% Procedure revenue of $37.4 million, up 6.6% Gross profit margin of 71.4%, an app.

Biote Reports First Quarter 2024 Financial Results

Biote Corp. (BTMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: biote Corp. (BTMD) Q1 Earnings Expected to Decline

IRVING, Texas--(BUSINESS WIRE)--biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced it has entered into a definitive settlement agreement (the “Settlement Agreement”) that concludes outstanding litigation with Dr. Gary S. Donovitz (“Donovitz”), founder and stockholder of Biote. The Settlement Agreement includes a mutual release of all clai.

Biote Announces Definitive Settlement with Founder

IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide first quarter financial results on Tuesday, May 7, 2024, after the close of the market. A conference call to discuss the firm's results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conference call may be a.

Biote Schedules First Quarter 2024 Financial Results Release and Conference Call

Pfizer

Progyny

VistaGen Therapeutics

Dare Bioscience

Menopause is among the female health conditions with the highest unmet need and has 'enormous potential for innovative treatments,' according to McKinsey.

This overlooked corner of women's health could be a $350 billion market opportunity

biote Corp. (BTMD) Q4 2023 Earnings Call Transcript

IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financial results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter 2023 Financial Highlights (All financial result comparisons made are against the prior-year period) Revenue of $45.7 million, a 2.7% increase and in line with pre-released financial guidance Proc.

Biote Reports Fourth Quarter and Full Year 2023 Financial Results

Analysts Estimate biote Corp. (BTMD) to Report a Decline in Earnings: What to Look Out for

IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide fourth quarter and full year financial results on Tuesday, March 12, 2024, after the close of the market. A conference call to discuss the firm's results will be held at 5:00 p.m. ET. the same day. Conference Call Details The confer.

Biote Schedules Fourth Quarter and Full Year 2023 Financial Results Release and Conference Call

IRVING, Texas--(BUSINESS WIRE)--biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced it has signed a binding term sheet with Dr. Gary S. Donovitz (“Donovitz”), founder and stockholder of Biote, to resolve outstanding litigation. In connection with this agreement, Biote will repurchase all of the Class A common units of Biote Holdings, LLC (.

Biote Announces Agreement to Resolve Litigation and Repurchase All of Founder's Shares

IRVING, Texas--(BUSINESS WIRE)--biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that its Board of Directors has approved a $20 million share repurchase program of the Company's common stock. This approval grants Biote's management the authority to repurchase outstanding shares of the Company's common stock, from time to time, in the op.

News for Biote Corp Stock (BTMD)